2006 — 2026
Twenty years of validated antibodies, rigorous science, and global impact.
OUR PRODUCTS
20 years of innovation
in one portfolio
Polyclonals, Monoclonals, Recombinant
Not just another antibody.
The right protein. In the right tissue.
With total confidence.
MolBoolean™ — Protein Interaction
Beyond Proximity Ligation. Quantify the complete protein profile — free, bound, and total — in a single experiment.
AtlasPlex — Custom Multiplex IHC
Multiplexing Made Simple. Detect multiple proteins in a single tissue section. Fully customisable panels.
"In 2006, a small lab in Stockholm set out to make the antibodies used to build the Human Protein Atlas available to every researcher worldwide. Two decades later, the antibodies are still the starting point for the discoveries of tomorrow."
20
years of validated antibodies
22k
validated primary antibodies
HPA
open access data integration
120
countries served worldwide
OUR ROOTS
born from the
Human Protein Atlas
“Imagine a company born not from a boardroom, but from the very heart of a monumental scientific mission.”
Atlas Antibodies was founded in 2006 as the commercial arm of one of the world's most ambitious science initiatives: the Human Protein Atlas which maps protein expression across all human tissues and organs.
We are the original manufacturer and our antibodies are built on that foundation.
TIMELINE
rooted in science,
built for researchers
20 years of advancing reproducible science
2000 — Human Genome Project completed. The race to map all the human proteins begins.
2003 — Human Protein Atlas initiated, funded by the Knut & Alice Wallenberg Foundation.
2006 — Atlas Antibodies founded. Triple-A Polyclonals bring Human Protein Atlas (HPA)–grade antibodies to market.
2012 — PrecisA Monoclonals launch. Precise, accurate and targeted mouse monoclonals.
2019 — Enhanced Validation. Application-specific validation data introduced across the catalogue, documenting how each antibody performs in the methods it's recommended for.
2021 — Acquisitions of HistoCyte (cell line controls) and evitria (recombinant antibody expression) expand the platform beyond primary antibodies.
2024 — MolBoolean protein proximity kit launch: quantifying free and interacting proteins in situ.
2025 — AtlasPlex multiplexing kit launch: a customizable multiplex IHC kit built on 12,000+ HPA-validated targets.
2026 — Recombinant Antibodies. Sequence-defined production for animal-free manufacturing and consistent lot-to-lot performance.
20 years, 22,000+ validated antibodies, 120+ countries, thousands of scientific references.
Application-specific validation
Validated for IHC, IF, WB, ICC and ChIP.
Full protocol and data transparency for every antibody.
HPA database integration
Every antibody linked to the Human Protein Atlas research database, giving you full expression context.
Gold-standard reproducibility
Consistent results across experiments and labs worldwide plus industry-leading validation methodology.